Trade Regulation

ORS 646A.697
Study of market for generic drugs

  • effect of pricing on insurance premiums
  • report to Legislative Assembly

(1)

As used in this section, “generic drug” means:

(a)

A retail drug that is marketed or distributed in accordance with an abbreviated new drug application approved under 21 U.S.C. 355(j);

(b)

An authorized generic as defined by 42 C.F.R. 447.502; or

(c)

A drug that entered the market before 1962 that was not originally marketed under a new drug application.

(2)

The Prescription Drug Affordability Board shall annually conduct a study of the operation of the United States market for generic drugs, both drugs dispensed by pharmacists and drugs administered by physicians, including:

(a)

The prices of generic drugs on a year-to-year basis;

(b)

The degree to which generic drug prices affect insurance premiums;

(c)

Annual changes in health insurance cost-sharing for generic drugs;

(d)

The potential for and history of generic drug shortages;

(e)

The degree to which generic drug prices affect annual spending in the state medical assistance program; and

(f)

Any other topic the board considers relevant to the cost of generic drugs.

(3)

No later than June 1 of each calendar year, the board shall report to the Legislative Assembly the findings of the board’s study in the manner provided in ORS 192.245 (Form of report to legislature). [2021 c.598 §6]
MORTGAGE RESCUE FRAUD PREVENTION ACT
(Foreclosure Consultants)
Source

Last accessed
May 26, 2023

REMOVE ADS